Payment overview · 2025
General Payments
$2,097.59
123 reported records · 24 companies
Healthcare provider profile · identity verified
Shubi Shahida, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SMITHFIELD, NC · NPI 1407803562
Verified facts
What the public records show
CMS Open Payments records show Shubi Shahida, MD received $2,097.59 in general payments during 2025 across 123 reported records.
AstraZeneca Pharmaceuticals LP accounted for 24.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 39 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Kerendia, Linzess, Mounjaro, Ozempic, Qulipta, Rybelsus, Trelegy Ellipta, Veozah.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Myrbetriq by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Veozah as an associated drug or biological on 82795 records involving 35863 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Veozah by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Kerendia by this doctor in 2024.
Esperion Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXLIZET as an associated drug or biological on 63 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Nexlizet by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 220 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 111 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 169 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 260 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $521.87 | 24.9% | 22 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $263.66 | 12.6% | 24 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $207.34 | 9.9% | 11 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $159.01 | 7.6% | 11 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $142.13 | 6.8% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $122.36 | 5.8% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $96.04 | 4.6% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $90.80 | 4.3% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $87.35 | 4.2% | 5 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $81.86 | 3.9% | 5 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $40.46 | 1.9% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $39.34 | 1.9% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $35.96 | 1.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $34.22 | 1.6% | 2 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $20.36 | 1.0% | 1 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $20.01 | 0.9% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.00 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.02 | 0.9% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $18.38 | 0.9% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $16.19 | 0.8% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $16.04 | 0.8% | 1 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $15.58 | 0.7% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $15.05 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $14.56 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,097.59 | 123 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $370.70 | 15 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $216.86 | 21 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $216.86 | 21 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $159.68 | 8 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $159.01 | 11 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $142.13 | 8 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $102.44 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $96.04 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $90.80 | 5 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $81.86 | 5 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $74.31 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $74.31 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $70.98 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $55.51 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $47.66 | 3 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $35.96 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $34.22 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $31.42 | 3 | 2025 |
Source payment records
|
|||||
| TRULANCE Normalized: trulance |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $23.17 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| XHANCE Normalized: xhance |
Drug | Paratek Pharmaceuticals, Inc. | $20.01 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $20.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.02 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $18.38 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.99 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.78 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $16.63 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $16.37 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.17 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $15.58 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $12.58 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 260 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 55 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 220 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 67 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 91 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 111 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 169 | exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 63 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 260 | exact normalized | Medicare Part D |
| Veozah veozah |
2025 | Veozah | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
155 | 30 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Veozah open payments reported associated product |
CMS Open Payments — General Payments 82795 supporting records · 35863 recipient NPIs · example record 1238560678 |
Veozah · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
55 | 15 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
67 | 12 |
| Esperion Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | NEXLIZET open payments reported associated product |
CMS Open Payments — General Payments 63 supporting records · 47 recipient NPIs · example record 1243951667 |
Nexlizet · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
260 | 44 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
220 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
111 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
49 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
169 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
63 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
260 | 51 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
42 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 1353 | 278 |
| Atorvastatin Calcium | Atorvastatin Calcium | 850 | 184 |
| Levothyroxine Sodium | Levothyroxine Sodium | 841 | 157 |
| Amlodipine Besylate | Amlodipine Besylate | 838 | 185 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 735 | 180 |
| Potassium Chloride | Potassium Chloride | 478 | 113 |
| Omeprazole | Omeprazole | 444 | 89 |
| Furosemide | Furosemide | 402 | 115 |
| Gabapentin | Gabapentin | 390 | 95 |
| Tramadol Hcl | Tramadol Hcl | 380 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 376 | 89 |
| Losartan Potassium | Losartan Potassium | 367 | 82 |
| Trazodone Hcl | Trazodone Hcl | 358 | 81 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 340 | 139 |
| Valsartan | Valsartan | 323 | 80 |
| Meloxicam | Meloxicam | 296 | 84 |
| Alprazolam | Alprazolam | 293 | 55 |
| Duloxetine Hcl | Duloxetine Hcl | 291 | 54 |
| Sertraline Hcl | Sertraline Hcl | 285 | 61 |
| Lisinopril | Lisinopril | 282 | 74 |
| Azithromycin | Azithromycin | 281 | 204 |
| Doxycycline Hyclate | Doxycycline Hyclate | 281 | 183 |
| Metformin Hcl Er | Metformin Hcl | 281 | 74 |
| Clopidogrel | Clopidogrel Bisulfate | 268 | 65 |
| Montelukast Sodium | Montelukast Sodium | 263 | 46 |
| Eliquis | Apixaban | 260 | 51 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 260 | 44 |
| Donepezil Hcl | Donepezil Hcl | 252 | 54 |
| Memantine Hcl | Memantine Hcl | 244 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 225 | 45 |
| Jardiance | Empagliflozin | 220 | 42 |
| Ezetimibe | Ezetimibe | 216 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 208 | 30 |
| Carvedilol | Carvedilol | 207 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 50 |
| Propranolol Hcl | Propranolol Hcl | 206 | 44 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 200 | 152 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 199 | 58 |
| Simvastatin | Simvastatin | 196 | 43 |
| Allopurinol | Allopurinol | 192 | 44 |
| Prednisone | Prednisone | 181 | 82 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 176 | 46 |
| Ozempic | Semaglutide | 169 | 40 |
| Metformin Hcl | Metformin Hcl | 165 | 35 |
| Pregabalin | Pregabalin | 164 | 39 |
| Celecoxib | Celecoxib | 158 | 33 |
| Famotidine | Famotidine | 158 | 36 |
| Spironolactone | Spironolactone | 158 | 34 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 156 | 35 |
| Synthroid | Levothyroxine Sodium | 155 | 30 |
| Clonazepam | Clonazepam | 153 | 30 |
| Glimepiride | Glimepiride | 149 | 34 |
| Tamsulosin Hcl | Tamsulosin Hcl | 147 | 40 |
| Alendronate Sodium | Alendronate Sodium | 146 | 34 |
| Mupirocin | Mupirocin | 140 | 98 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 138 | 91 |
| Torsemide | Torsemide | 138 | 27 |
| Paroxetine Hcl | Paroxetine Hcl | 136 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 135 | 49 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 135 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 134 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 132 | 29 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 131 | 24 |
| Levofloxacin | Levofloxacin | 127 | 100 |
| Atenolol | Atenolol | 120 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 117 | 41 |
| Mirtazapine | Mirtazapine | 113 | 20 |
| Mounjaro | Tirzepatide | 111 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 110 | 20 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 108 | 23 |
| Cefdinir | Cefdinir | 107 | 77 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 102 | 22 |
| Lorazepam | Lorazepam | 101 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 100 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 99 | 18 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 97 | 27 |
| Amitriptyline Hcl | Amitriptyline Hcl | 96 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 96 | 14 |
| Bupropion Xl | Bupropion Hcl | 94 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 91 | 20 |
| Linzess | Linaclotide | 91 | 19 |
| Promethazine Hcl | Promethazine Hcl | 91 | 15 |
| Verapamil Er | Verapamil Hcl | 91 | 13 |
| Buspirone Hcl | Buspirone Hcl | 88 | 25 |
| Ropinirole Hcl | Ropinirole Hcl | 88 | 12 |
| Glipizide Er | Glipizide | 87 | 19 |
| Fenofibrate | Fenofibrate | 85 | 15 |
| Sucralfate | Sucralfate | 84 | 18 |
| Fluconazole | Fluconazole | 83 | 55 |
| Januvia | Sitagliptin Phosphate | 83 | 14 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 83 | 17 |
| Temazepam | Temazepam | 83 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 82 | 30 |
| Meclizine Hcl | Meclizine Hcl | 80 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 79 | 20 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 79 | 16 |
| Topiramate | Topiramate | 79 | 15 |
| Telmisartan | Telmisartan | 74 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 15 |
| Kerendia | Finerenone | 67 | 12 |
| Baclofen | Baclofen | 65 | 13 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 65 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 64 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 64 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 64 | 14 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 64 | 17 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 63 | 24 |
| Rybelsus | Semaglutide | 63 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 62 | 48 |
| Levetiracetam | Levetiracetam | 61 | 13 |
| Diazepam | Diazepam | 59 | 18 |
| Irbesartan | Irbesartan | 59 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 58 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 57 | 17 |
| Farxiga | Dapagliflozin Propanediol | 55 | 15 |
| Methylprednisolone | Methylprednisolone | 55 | 51 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 15 |
| Ramipril | Ramipril | 54 | 12 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 53 | 25 |
| Hydrocortisone | Hydrocortisone | 53 | 33 |
| Methocarbamol | Methocarbamol | 53 | 16 |
| Clobetasol Propionate | Clobetasol Propionate | 51 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 50 | 14 |
| Entresto | Sacubitril/Valsartan | 49 | suppressed |
| Glipizide | Glipizide | 49 | suppressed |
| Naproxen | Naproxen | 48 | 26 |
| Nifedipine Er | Nifedipine | 47 | suppressed |
| Cephalexin | Cephalexin | 46 | 41 |
| Valacyclovir | Valacyclovir Hcl | 45 | 18 |
| Benazepril Hcl | Benazepril Hcl | 44 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 44 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 44 | suppressed |
| Tradjenta | Linagliptin | 44 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 44 | 31 |
| Bupropion Hcl Sr | Bupropion Hcl | 43 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 42 | 40 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 41 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 40 | 13 |
| Tresiba Flextouch U-200 | Insulin Degludec | 40 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 39 | suppressed |
| Myrbetriq | Mirabegron | 39 | suppressed |
| Bumetanide | Bumetanide | 38 | 11 |
| Rabeprazole Sodium | Rabeprazole Sodium | 38 | suppressed |
| Zafirlukast | Zafirlukast | 38 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 37 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 37 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 37 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 36 | 32 |
| Nystatin | Nystatin | 35 | 23 |
| Estradiol | Estradiol | 34 | 16 |
| Fentanyl | Fentanyl | 34 | suppressed |
| Levemir Flexpen | Insulin Detemir | 34 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 34 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 34 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 34 | suppressed |
| Trulicity | Dulaglutide | 34 | suppressed |
| Metronidazole | Metronidazole | 33 | 24 |
| Ondansetron Odt | Ondansetron | 33 | 13 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Amiloride Hcl | Amiloride Hcl | 30 | suppressed |
| Lansoprazole | Lansoprazole | 30 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 30 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | 14 |
| Ibuprofen | Ibuprofen | 29 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 29 | 18 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Febuxostat | Febuxostat | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 28 | suppressed |
| Roflumilast | Roflumilast | 28 | suppressed |
| Amoxicillin | Amoxicillin | 27 | 17 |
| Divalproex Sodium | Divalproex Sodium | 27 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 27 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 26 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 26 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 26 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 25 | 11 |
| Dexamethasone | Dexamethasone | 25 | 23 |
| Nabumetone | Nabumetone | 25 | 13 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 25 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 24 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 24 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 23 | suppressed |
| Clarithromycin | Clarithromycin | 23 | 22 |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 22 | suppressed |
| Novolog Flexpen | Insulin Aspart | 22 | 11 |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 21 | suppressed |
| Ketoconazole | Ketoconazole | 21 | 14 |
| Spiriva Handihaler | Tiotropium Bromide | 21 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 20 | 15 |
| Pitavastatin Calcium | Pitavastatin Calcium | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Perphenazine | Perphenazine | 19 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 19 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Brilinta | Ticagrelor | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 18 | suppressed |
| Movantik | Naloxegol Oxalate | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Carbamazepine Er | Carbamazepine | 17 | suppressed |
| Indapamide | Indapamide | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Nitroglycerin | Nitroglycerin | 17 | 13 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 14 |
| Belsomra | Suvorexant | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Lovastatin | Lovastatin | 16 | suppressed |
| Lubiprostone | Lubiprostone | 16 | suppressed |
| Niacin Er | Niacin | 15 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 14 | suppressed |
| Dofetilide | Dofetilide | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Nucynta | Tapentadol Hcl | 14 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 13 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Danazol | Danazol | 13 | suppressed |
| Dilantin | Phenytoin Sodium Extended | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Dupixent Pen | Dupilumab | 13 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 13 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Qulipta | Atogepant | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Ulticare Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Acetazolamide | Acetazolamide | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Cholestyramine Light | Cholestyramine | 12 | suppressed |
| Desloratadine | Desloratadine | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Methylphenidate Er | Methylphenidate Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Veozah | Fezolinetant | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Calcitriol | Calcitriol | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 11 | 11 |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
| Trijardy Xr | Empaglifloz/Linaglip/Metformin | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,097.59 · 123 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, CAPLYTA, CAPVAXIVE, ELIQUIS, EVENITY, FANAPT, FARXIGA, HETLIOZ, INSPIRE, JARDIANCE, KISUNLA, KRYSTEXXA, Kerendia, Korlym, LEQVIO, LINZESS, Leqembi, MOUNJARO, NEXLETOL, NURTEC ODT, NUZYRA, OTEZLA, Ohtuvayre, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, TONMYA, TRELEGY ELLIPTA, TRULANCE, UBRELVY, VERQUVO, VOQUEZNA, Veozah, Wegovy, XHANCE, XIFAXAN, ZEPBOUND | 20 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error